EWTX
NASDAQEdgewise Therapeutics Inc.
Edgewise Therapeutics Inc. (EWTX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for EWTX, including 2 press releases and news items, 2 SEC filings and 1 analyst rating. The most recent was published Nov 4, 2026.
EWTX rankings
Price$37.58-0.79 (-2.05%)
02:30 PM08:45 PM
Financial highlights
Full financials- Net income, TTM
- -$197.22M
- Free cash flow, TTM
- -$158.83M
- Cash
- $72.32M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks54+25%
2026-05-102026-11-01
Mix2490d
- Insider12(50%)
- Other6(25%)
- SEC Filings3(13%)
- Earnings2(8%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form 10-Q filed by Edgewise Therapeutics Inc.10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- SECEdgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- PREdgewise Therapeutics Reports Third Quarter 2026 Financial Results– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain –– Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 –– Dosed first patient in Phase 2 EQUINOX-HFpEF trial of EDG-15400 in heart failure with preserved ejection fraction (HFpEF) –BOULDER, Colo., Nov. 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today reported financial results for the third quarter of 2026 and recent business highlights. "Our third quarte
- PREdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesBOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that on October 30, 2026, Edgewise granted inducement stock options to purchase a total of 17,250 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 8,626 shares of Edgewise's common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
- ANALYSTWilliam Blair initiated coverage on Edgewise TherapeuticsWilliam Blair initiated coverage of Edgewise Therapeutics with a rating of Outperform
- PREdgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400– Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% –– EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 –BOULDER, Colo., Oct. 8, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiometabolic diseases, today announced the dosing of the first patient in EQUINOX-HFpEF, a Phase 2 clinical trial evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction (HFpEF) who have a left ventricular ejection fraction (LVEF) of at least 50%.EDG-15400 is an investigational, oral, selective cardiac sarc
- INSIDERDirector Fox Jonathan C was granted 308 shares, increasing direct ownership by 1% to 25,141 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- PREdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesBOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on September 30, 2026, Edgewise granted inducement stock options to purchase a total of 7,500 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 3,751 shares of Edgewise's common stock to 3 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). Each inducement stock option has an ex
- PREdgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve -- Company to host webcast to discuss these findings today at 8:30 a.m. Eastern Time -BOULDER, Colo., Sept. 22, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that it will host an investor conference call to discuss the preclinical pharmacologic profile of EDG-7500, a first-in-class cardiac sarcomere modulator targeting the RLC. Data will be provided supporting EDG-7500's ability to improve cardiac relax
- PREdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesBOULDER, Colo., Sept. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on August 31, 2026, Edgewise granted inducement stock options to purchase a total of 21,000 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 10,501 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
- PREdgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation in symptomatic HCM while
- INSIDERAmendment: SEC Form 4 filed by Chief Financial Officer Nofi Michael4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by CMO Donovan Joanne M.4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Scientific Officer Russell Alan J4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by General Counsel Moore John R4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Business Officer Derakhshan Behrad4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Nofi Michael4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERGeneral Counsel Moore John R converted options into 12,499 shares and sold $219,823 worth of shares (5,016 units at $43.82), increasing direct ownership by 73% to 17,697 units (SEC Form 4) (for tax liability)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERCMO Donovan Joanne M. converted options into 12,812 shares and sold $412,703 worth of shares (9,441 units at $43.71) as part of a pre-agreed trading plan, increasing direct ownership by 64% to 8,625 units (SEC Form 4) (for tax liability)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERChief Scientific Officer Russell Alan J converted options into 12,812 shares and sold $258,042 worth of shares (5,901 units at $43.73), increasing direct ownership by 28% to 31,466 units (SEC Form 4) to satisfy withholding obligation4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERChief Business Officer Derakhshan Behrad converted options into 13,281 shares and sold $223,424 worth of shares (5,100 units at $43.81), increasing direct ownership by 35% to 31,826 units (SEC Form 4) to cover taxes4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERPresident and CEO Koch Kevin converted options into 39,844 shares and sold $785,042 worth of shares (17,971 units at $43.68), increasing direct ownership by 71% to 52,488 units (SEC Form 4) (withholding obligation)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Edgewise Therapeutics Inc.SCHEDULE 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- SECSEC Form 144 filed by Edgewise Therapeutics Inc.144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- SECSEC Form SCHEDULE 13G filed by Edgewise Therapeutics Inc.SCHEDULE 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)
EWTX FAQ
10 questionsWhat does Edgewise Therapeutics Inc. do?
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.What is the latest news on EWTX?
In the last 30 days Quantisnow tracked 6 wire items for EWTX: 2 press releases and news items, 2 SEC filings, 1 analyst rating and 1 earnings update. The most recent was published on November 4, 2026.Is EWTX profitable?
No. Edgewise Therapeutics Inc. reported a net loss of $197.22M for the twelve months ended Jun 30, 2026.How much cash and debt does EWTX have?
Edgewise Therapeutics Inc. reported $72.32M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does EWTX stock trade?
Edgewise Therapeutics Inc. (EWTX) is listed on NASDAQ.What sector and industry is EWTX in?
Edgewise Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Edgewise Therapeutics Inc. go public?
Edgewise Therapeutics Inc. (EWTX) completed its IPO in 2021.What are analysts saying about EWTX?
Across the last 8 analyst actions on Edgewise Therapeutics Inc., there were 0 upgrades and 1 downgrade. The most recent action was from William Blair: Outperform on 2026-10-16. Recent price targets range from $14.00 to $51.00.What companies are similar to EWTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EWTX side-by-side with any of them on Quantisnow.How can I track EWTX on Quantisnow?
Quantisnow aggregates Edgewise Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EWTX to receive live email and push alerts on every new disclosure.